Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NORTH CHICAGO, Ill. , Sept. 6, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share.

AbbVie Declares Quarterly Dividend

Bristol-Myers

Pfizer

Pharmaceutical (PPH) stocks have done relatively well this year. The closely watched iShares US Pharmaceutical ETF (IHE) stock has jumped by 16.5%, slightly beating the S&P 500 index, which has risen by 16.3%.

Pharma stocks analysis: Pfizer, Bristol-Myers Squibb, AbbVie

Hims & Hers Health

UnitedHealth Group

Hims & Hers is rapidly picking up steam in the telehealth industry. UnitedHealth's dominance has created massive wealth for long-term investors.

Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.

AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?

AbbVie NYSE: ABBV is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's success has propelled AbbVie to great heights, its recent patent expiration has greatly influenced the company's future.

AbbVie Stock Post Humira is Still an Attractive Stock to Hold

CHICAGO--(BUSINESS WIRE)--The AbbVie Foundation, a 501(c)(3) nonprofit working to drive transformative change and advance health equity in communities worldwide, in partnership with MATTER, the premier healthcare incubator and innovation hub, announce the launch of the AbbVie Foundation Health Equity Accelerator. The Accelerator will support the advancement of innovative, scalable solutions and programs that rethink the delivery, space and place of care for underserved communities with limited.

The AbbVie Foundation and MATTER Launch the AbbVie Foundation Health Equity Accelerator

AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 - jumping from levels of $90 then to around $195 now - vs. an increase of about 50% for the S&P 500 over this period.

What's Behind The 2x Jump In AbbVie Stock?

Merck

These two companies sell products that remain in high demand even during recessions. They also have excellent dividend track records -- and one of them is a Dividend King.

2 Dividend Stocks You Can Safely Hold Through a Recession

AT&T

Historically, September is a relatively bad month for stock markets. AT&T offers a huge dividend yield and it could start raising the payout again next year.

2 High-Yield Dividend Stocks to Buy in September and Hold for a Decade or Longer

Cava Group, Inc.

Consumers are still spending money on healthcare and fast-casual dining. AbbVie is a faithful dividend payer with a blockbuster portfolio.

2 Monster Stocks You Can Buy Right Now Before They Surge Even Higher

Abbott Labs

Vertex Pharmaceuticals

Abbott Labs produces medications as just one of its revenue sources. AbbVie has shown a knack for expanding the markets of its drugs.

3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever

Both of these stocks have something to offer income-seeking investors. AbbVie is moving on from the loss of patent exclusivity for the world's top-selling drug.

2 Incredibly Cheap Healthcare Stocks to Buy Now

AbbVie's stock has risen to an all-time high, raising the question of whether it's still a good buy, especially as the market multiples look elevated from a historical perspective. Progress on its treatments, particularly for Inflammatory Bowel Disease, is encouraging. This is key, as the market for the disease is growing with its rising incidence impacted by lifestyle factors. The company's revenue turnaround after the patent expiration for Humira also continues, though the profits could be better.

AbbVie: Promising Developments On IBD Treatments

AbbVie delivered Y/Y growth in the second quarter despite Humira's decline, with Skyrizi and Rinvoq as key growth drivers, achieving 45% and 56% Y/Y growth, respectively. I expect Skyrizi to become a bigger product for AbbVie than Humira was at its peak in 2021. Skyrizi's robust efficacy and good safety in psoriasis, psoriatic arthritis, and inflammatory bowel diseases support its strong long-term growth prospects.

AbbVie Already Has The Next Humira

Lowe's

AbbVie is a Dividend King that has proven it can successfully navigate challenges. Lowe's Companies is a great stock to own over the long run because homes will always need to be fixed up.

Bull Market Buys: 3 Dividend Stocks to Own for the Long Run

Aldeyra Therapeutics

Aldeyra Therapeutics' Reproxalap eye drop for Dry Eye Disease has new positive data for the second NDA attempt. Aldeyra has an option agreement with AbbVie, potentially leading to significant milestone payments and a 60%/40% partnership if FDA approval is granted. Reproxalap offers immediate and long-term relief, a significant advantage over existing therapies like Xiidra and Restasis, enhancing its market potential.

Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership

Intuitive Surgical

3 Best Growth Stocks to Own for the Next 10 Years

Apple

AGNC Investment

Antero Midstream Partners

Apple Hospitality REIT

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

bluebird bio

Bank of Montreal

Bayerische Motoren Werke AG

Bank of Nova Scotia

BRT Apartments

Blackstone Group

Blackstone Secured Lending Fund

Colgate-Palmolive

Investment activity in July focused on Business Development Companies, with $2,000 added to the market. Adjusted dividend income in July of $709, up 19% Y/Y and down 4% sequentially. Main picks included Blackstone Secured Lending, Ares Capital and Owl Rock Capital.

My Dividend Stock Portfolio: New July Dividend Record - 101 Holdings With 24 Buys

AbbVie is one of my biggest winners and a top 10 holding in my portfolio. The company's increasing contributions from Skyrizi and Rinvoq pushed net revenue higher in Q2. AbbVie maintains its A- credit rating from S&P on a stable outlook.

AbbVie: I'm Up 149% And Holding This Dividend Aristocrat Now

AbbVie has shown strong growth, especially in immunology and oncology, with Skyrizi and Rinvoq driving impressive sales and long-term growth potential. Despite Humira's patent loss, AbbVie has managed a "soft landing" and continues to innovate, particularly in neuroscience and oncology. The company offers a solid dividend with a 51% payout ratio and consistent growth, making it attractive for conservative investors seeking income and growth.

Why AbbVie Remains One Of My Favorite Dividend Growers

Altria

A recession is looming. Despite the S&P 500 nearing its all-time high, the yield curve inverted and the

2 Stocks to Buy Now Before a Stock Market Crash

More than 400 undergraduate and graduate students in the U.S. have benefited from the AbbVie Immunology Scholarship since its inception in 2016 NORTH CHICAGO, Ill. , Aug. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the 2024-2025 recipients of the AbbVie Immunology Scholarship, aimed to support students living with chronic, inflammatory diseases as they pursue higher education.

AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases

SkinMedica®, by the makers of BOTOX® Cosmetic (onabotulinumtoxinA) launches the first and only product to use a proprietary complex of five forms of Hyaluronic Acid (HA) and Hydra Collagen, plus Advanced VITISENSCE® Technology for deeper hydration IRVINE, Calif. , Aug. 27, 2024 /PRNewswire/ -- For 25 years, SkinMedica® has been at the forefront of science-based skincare solutions, and today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of its next generation hydration product: SkinMedica® HA5® Hydra Collagen Replenish + Restore Hydrator.

SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator

Cigna

Cigna said on Monday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead.

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year

ATLANTA--(BUSINESS WIRE)---- $ABBV #505b2_pathway_for_FDA_approval--Alzamend Neuro Issues Letter to Stockholders; recently announced partnership with Mass. General Hospital for 5 Phase II clinical trials of AL001.

News for AbbVie Stock (ABBV)